AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Use of computational software in drug research is growing, and some big tech companies are angling for a piece of this market. Cadence Design Systems is entering the life sciences sector through the $500 million acquisition of OpenEye Scientific, a company that provides computational drug design software to the pharmaceutical industry.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. In other M&A news, cancer biotech F-star Therapeutics is being acquired in a $161 million deal.
AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential applications in a range of cognitive disorders. Syndesi is based on research from Belgian pharmaceutical company UCB.
According to a report by professional services firm EY, companies that want to grow, focus and innovate will drive dealmaking in 2020, though activity may not reach the record level set in 2019 — $357 billion as of the end of November.
Abbott Labs filed a complaint in a Delaware court citing that Alere has numerous problems and the court should allow it to bow out of its proposed plan to buy Alere for $5.8 billion.
How to turn analytics into actual policy outcomes.
International M&A in the life sciences is picking up steam, according to a new Mergermarket report - with new focus on the fields of early stage drug discovery and precision medicine.